Premier Asset Management LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,700 shares of the life sciences company’s stock, valued at approximately $1,410,000.
A number of other large investors have also recently bought and sold shares of ILMN. Proficio Capital Partners LLC raised its position in shares of Illumina by 61.7% during the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Colony Group LLC boosted its stake in shares of Illumina by 3.3% during the 4th quarter. Colony Group LLC now owns 1,172 shares of the life sciences company’s stock worth $352,000 after buying an additional 37 shares during the last quarter. Whittier Trust Co. boosted its stake in shares of Illumina by 1.7% during the 4th quarter. Whittier Trust Co. now owns 2,697 shares of the life sciences company’s stock worth $809,000 after buying an additional 44 shares during the last quarter. Paradigm Asset Management Co. LLC boosted its stake in shares of Illumina by 8.3% during the 3rd quarter. Paradigm Asset Management Co. LLC now owns 650 shares of the life sciences company’s stock worth $239,000 after buying an additional 50 shares during the last quarter. Finally, FTB Advisors Inc. boosted its stake in shares of Illumina by 35.7% during the 4th quarter. FTB Advisors Inc. now owns 190 shares of the life sciences company’s stock worth $56,000 after buying an additional 50 shares during the last quarter. 90.46% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages recently issued reports on ILMN. OTR Global downgraded shares of Illumina to a “positive” rating in a research note on Tuesday, April 2nd. Leerink Swann upgraded shares of Illumina to an “outperform” rating and cut their price objective for the stock from $380.00 to $365.00 in a research report on Wednesday, January 30th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Monday, December 31st. BidaskClub cut shares of Illumina from a “hold” rating to a “sell” rating in a report on Tuesday, January 29th. Finally, UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and raised their target price for the stock from $340.00 to $370.00 in a report on Thursday, January 3rd. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Illumina has a consensus rating of “Buy” and a consensus price target of $346.97.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by ($0.04). The firm had revenue of $867.00 million during the quarter, compared to analyst estimates of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. Illumina’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.44 EPS. Research analysts expect that Illumina, Inc. will post 6.53 earnings per share for the current year.
In other Illumina news, SVP Charles Dadswell sold 124 shares of the business’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $280.11, for a total value of $34,733.64. Following the transaction, the senior vice president now directly owns 6,879 shares in the company, valued at $1,926,876.69. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $317.01, for a total transaction of $1,046,133.00. Following the completion of the transaction, the director now owns 331,668 shares in the company, valued at $105,142,072.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,826 shares of company stock valued at $10,604,560. 0.54% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/15/premier-asset-management-llc-purchases-new-stake-in-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Average Daily Trade Volume – ADTV
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.